Deucravacitinib

COMPOSITION:

Each film-coated tablet contains Deucravacitinib……………………………………. 6mg.

INDICATION:

LuciDeucra is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

DOSAGE AND USE:

• For recommended evaluation prior to LuciDeucra initiation, see Full Prescribing Information.

• Recommended dosage is 6 mg orally once daily, with or without food.

LIMITATIONS OF USE:

Not recommended for use in combination with other potent immunosuppressants.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciDeucra during Pregnancy and Lactation.